PTGS2 and renal cell carcinoma: In particular, SPP1 expression demonstrated increased levels in the progressing group and decreased levels in the regressing group within an RCC cohort, underscoring its potential as an indicator in immunotherapy [28], while high expression of PTGS2 mRNA is a poor prognostic indicator in human mccRCC [29].